GRI Bio, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Matthew Keller from H.C. Wainwright reiterated a Buy rating on the stock and has a $10.00 price target.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Matthew Keller’s rating is based on the promising interim results from GRI Bio’s ongoing Phase 2a study, which suggest that their drug, GRI-0621, is effectively providing an anti-fibrotic effect in patients with idiopathic pulmonary fibrosis (IPF). The study has shown a favorable safety profile and extensive biomarker data that support the drug’s efficacy, which helps mitigate risks for future results.
Additionally, the trial is fully enrolled, and the company is on track to release topline results by the end of the year. Despite the short duration of the study so far, the absence of worsening lung function in patients is a positive sign. These factors, combined with the company’s financial position and ongoing favorable safety reviews, contribute to Keller’s Buy rating for GRI Bio.